1.12
price down icon3.45%   -0.04
after-market Dopo l'orario di chiusura: 1.11 -0.01 -0.89%
loading
Precedente Chiudi:
$1.16
Aprire:
$1.15
Volume 24 ore:
28,394
Relative Volume:
0.14
Capitalizzazione di mercato:
$37.56M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-6.8293
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
+0.00%
1M Prestazione:
+4.67%
6M Prestazione:
-26.32%
1 anno Prestazione:
-37.78%
Intervallo 1D:
Value
$1.10
$1.1664
Intervallo di 1 settimana:
Value
$1.10
$1.30
Portata 52W:
Value
$0.8075
$2.12

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Nome
Okyo Pharma Limited
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-30
Name
Ultimi documenti SEC
Name
OKYO's Discussions on Twitter

Okyo Pharma Limited Borsa (OKYO) Ultime notizie

pulisher
Oct 30, 2024

OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA

Oct 30, 2024
pulisher
Oct 30, 2024

OKYO Pharma Advances in Ocular Treatment Trials - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times

Oct 30, 2024
pulisher
Oct 26, 2024

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors USA

Oct 26, 2024
pulisher
Oct 25, 2024

H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors UK

Oct 24, 2024
pulisher
Oct 24, 2024

OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena

Oct 24, 2024
pulisher
Oct 24, 2024

H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India

Oct 24, 2024
pulisher
Oct 23, 2024

OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive Investors USA

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.

Oct 23, 2024
pulisher
Oct 21, 2024

Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK

Oct 17, 2024
pulisher
Oct 17, 2024

OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors Australia

Oct 16, 2024
pulisher
Oct 16, 2024

OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire

Oct 16, 2024
pulisher
Oct 04, 2024

OKYO Pharma (NASDAQ:OKYO) Shares Up 3% – What’s Next? - Defense World

Oct 04, 2024
pulisher
Oct 01, 2024

Neuropathic Ocular Pain Market Overview: Size, Growth - openPR

Oct 01, 2024
pulisher
Sep 24, 2024

Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News

Sep 24, 2024
pulisher
Sep 23, 2024

Understanding OKLO’s book value per share for better investment insights - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now

Sep 23, 2024
pulisher
Sep 23, 2024

Ok Play's board approves allotment of Equity sharesCheck details - India.com

Sep 23, 2024
pulisher
Sep 23, 2024

Oklo Inc. (NYSE:OKLO) Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share - MarketBeat

Sep 23, 2024
pulisher
Sep 21, 2024

XTX Topco Ltd Acquires Shares of 33,954 Omega Healthcare Investors, Inc. (NYSE:OHI) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Traders Buy High Volume of Oklo Call Options (NYSE:OKLO) - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Orkla India eyes public listing after completing restructuring | Company Business News - Mint

Sep 20, 2024
pulisher
Sep 19, 2024

Tomohiro Okada named president, director of Universal Ent - GGRAsia

Sep 19, 2024
pulisher
Sep 19, 2024

Multibagger Penny Stock Under Rs 20 Surges Over 50 Per Cent From Its 52-Week Low; Board Allots Equity Shares On Conversion Of Warrants To Promoters - Dalal Street Investment Journal

Sep 19, 2024
pulisher
Sep 19, 2024

OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Oklo Inc. (OKLO) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Sep 18, 2024
pulisher
Sep 11, 2024

OKYO Pharma executive chairman increases stake - Investing.com

Sep 11, 2024
pulisher
Sep 11, 2024

OKYO Pharma executive increases stake in company By Investing.com - Investing.com Australia

Sep 11, 2024
pulisher
Sep 10, 2024

OKYO Pharma executive chairman increases stake By Investing.com - Investing.com UK

Sep 10, 2024
pulisher
Sep 10, 2024

OKYO Pharma executive increases stake in company - Investing.com

Sep 10, 2024
pulisher
Sep 10, 2024

OKYO Pharma Chairman Boosts Stake, Advances Trials - TipRanks

Sep 10, 2024
pulisher
Sep 10, 2024

Okyo Pharma announces acquisition of shares by chairman - TipRanks

Sep 10, 2024
pulisher
Sep 10, 2024

OKYO Pharma Announces Chairman Acquires Shares - GlobeNewswire

Sep 10, 2024
pulisher
Sep 10, 2024

OKYO Pharma chair increases shareholdings - Proactive Investors UK

Sep 10, 2024
pulisher
Sep 06, 2024

OKYO Pharma executive increases stake - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

OKYO Pharma Ltd expected to post a loss of 11 cents a shareEarnings Preview - XM

Sep 06, 2024

Okyo Pharma Limited Azioni (OKYO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):